Tradestie Institutional Equity Comparison Engine

GILD vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GILD Overall Edge

GILD Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Gilead Sciences Inc (GILD) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, GILD trades at 16.4x Forward P/E with 38.2% operating margin (+6.8% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, GILD sits in SURGE (61st %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GILD
GILD 16.4x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner GILD
Op Margin 38.2% vs -80.8% ยท YoY +6.8% vs +29.2%
Momentum & Technical Winner MRNA
1Y +29.9% vs +706.5% ยท 52W Pos 83% vs 67%
Options & Structure Winner GILD
SURGE (61st %ile IV) vs CONSOLIDATION (52nd %ile IV)
GILD NASDAQ
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$166.43
-0.06% 1D
Market Cap $206.6B
1M Return +5.88%
1Y Return +29.95%
Forward P/E 16.4x
Unified AI Score
42.9 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 68.0 Mom 50.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GILD +29.95% MRNA +706.45% Spread: +676.5 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period GILD Revenue MRNA Revenue GILD Op. Margin MRNA Op. Margin Margin Edge
FY2018 $22.1B $140M 37.1% -306.0% GILD
FY2019 $22.4B $60M 19.1% -906.8% GILD
FY2020 $24.7B $800M 16.5% -95.0% GILD
FY2021 $27.3B $18.5B 36.3% 72.0% MRNA
FY2022 $27.3B $19.3B 26.9% 48.9% MRNA
FY2023 $27.1B $6.85B 28.0% -61.9% GILD
FY2024 $28.8B $3.24B 5.8% -121.9% GILD
FY2025 $29.4B $1.94B 34.0% -158.1% GILD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GILD (9) vs MRNA (1)
Institutional Metric GILD MRNA Criterion Row Winner
Market Capitalization Scale $206.6B $80.7B Larger Scale GILD
Trailing P/E Ratio Valuation 16.8x 23.0x Lower Multiple GILD
Forward P/E Ratio Valuation 16.4x 23.0x Lower Multiple GILD
Revenue Growth (YoY) Growth +6.8% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability 38.2% -80.8% Higher Margin GILD
Net Profit Margin Profitability -12.5% -110.5% Higher Margin GILD
Return on Equity (ROE) Capital Efficiency -22.4% -34.5% Higher ROE GILD
52-Week Range Position Momentum 83% ($117โ€“$177) 67% ($22โ€“$281) Stronger Trend GILD
Beta / 30D Volatility Risk Regime 0.31ฮฒ ยท 30% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk GILD
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite GILD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GILD vs MRNA Buy Guide
GILD SURGE
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 61st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live GILD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GILD nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.